Alector Inc
NASDAQ:ALEC

Watchlist Manager
Alector Inc Logo
Alector Inc
NASDAQ:ALEC
Watchlist
Price: 1.44 USD 3.6% Market Closed
Market Cap: 157.2m USD

Operating Margin
Alector Inc

-179.1%
Current
-172%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-179.1%
=
Operating Profit
-123.7m
/
Revenue
69m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Alector Inc
NASDAQ:ALEC
154.7m USD
-179%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
401B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.9B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
155.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.3B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
45B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.3B USD
8%
No Stocks Found

Alector Inc
Glance View

Market Cap
154.7m USD
Industry
Biotechnology

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

ALEC Intrinsic Value
1.27 USD
Overvaluation 12%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-179.1%
=
Operating Profit
-123.7m
/
Revenue
69m
What is the Operating Margin of Alector Inc?

Based on Alector Inc's most recent financial statements, the company has Operating Margin of -179.1%.

Back to Top